- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
UCLA Study Points to Need for Informed Decision-Making in Prostate Cancer
The study evaluated SEER data of over 37,000 prostate cancer patients and found an overwhelming majority of patients (58%) received radiation treatment regardless of overall disease prognosis. The lead study author hopes these findings enlighten the public and allow physicians to make an informed decision when it comes to the best treatment option for men who may or may not benefit from radiation therapy in the long run.
LA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.
Led by UCLA Jonsson Comprehensive Cancer Center member Dr. Karim Chamie, the observational study analyzed the claims data of over 37,000 patients over a three-year period (2004 to 2007), provided by the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute (NCI).
The research was conducted at UCLA and Chamie's team found that radiation therapy was the most common treatment at 58%, followed by radical prostatectomy (a surgical procedure to remove the prostate) at 19%. Other treatments trailed at 10%, including watchful waiting (where doctors wait and see if cancer progresses before treating it) and active surveillance (when patients undergo routine biopsies, blood tests and MRI to determine if cancer is progressing and undergo active treatment).
Read the complete article on ScienceDaily: http://bit.ly/1AXSfyo
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
